Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 3,285 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Progenitor Cells Clear all
Completed Not applicable Interventional Results available

HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt

NCT02073565
View directory record Official record
Conditions
Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
Interventions
OrbusNeich Combo stent™, Everolimus Eluting Stent (EES)
Device
Lead sponsor
OrbusNeich
Industry
Eligibility
20 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
17
States / cities
Washington D.C., District of Columbia • Lake Worth, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 30, 2026, 11:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

SCID Bu/Flu/ATG Study With T Cell Depletion

NCT02127892
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
unrelated BM with T cell depletion, unrelated cord blood, haplo BM with T cell depletion, unrelated PBSC with T cell depletion
Biological · Device
Lead sponsor
Neena Kapoor, M.D.
Other
Eligibility
Up to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 30, 2026, 11:43 AM EDT
Completed Not applicable Interventional

Impact of Prehabilitation in Oncology Via Exercise- Bone Marrow Transplant

NCT03886909
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant, Hematologic Diseases, Physical Activity, Prehabilitation
Interventions
Exercise, Prehabilitation Education
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 30, 2026, 11:43 AM EDT
Recruiting Phase 1 Interventional

Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

NCT07573111
View directory record Official record
Conditions
Acute Leukemia, Myelodysplastic Syndrome
Interventions
QUAIL-100
Biological
Lead sponsor
Laguna Biotherapeutics, Inc.
Industry
Eligibility
18 Months to 39 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 11:43 AM EDT
Recruiting Phase 1 Interventional

Safety of Cultured Umbilical or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CP

NCT05018871
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Umbilical or placental derived mesenchymal stem cells
Biological
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Naples, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 11:43 AM EDT
Recruiting Phase 1Phase 2 Interventional

Stem Cell Therapy for Early Alzheimer's Disease

NCT06775964
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
adMSC
Biological
Lead sponsor
Paul E Schulz
Other
Eligibility
60 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 30, 2026, 11:43 AM EDT
Terminated Not applicable Interventional Results available

Stem Cell Transplant for Hematological Malignancy

NCT00176930
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MDS, Leukemia, Lymphocytic, Chronic, JMML, Hodgkin's Disease, Non-hodgkin's Lymphoma, Multiple Myeloma
Interventions
Stem Cell Transplant, Cyclophosphamide, Total Body Irradiation, Busulfan, Equine ATG (ATGAM), CD4+/CD25+ cells
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 30, 2026, 11:43 AM EDT
Completed Phase 1Phase 2 Interventional

Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy

NCT01345006
View directory record Official record
Conditions
Stargardt's Macular Dystrophy
Interventions
MA09-hRPE
Biological
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 30, 2026, 11:43 AM EDT
Withdrawn No phase listed Observational

Adenovirus and Fungal Load in Pediatric Stem Cell Transplant Patients

NCT00448994
View directory record Official record
Conditions
Adenovirus, Other Mycoses
Interventions
Not listed
Lead sponsor
Steven B. Kleiboeker
Industry
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Kansas City, Missouri • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 30, 2026, 11:43 AM EDT
Withdrawn Phase 2 Interventional

Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD

NCT05333029
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP)
Biological
Lead sponsor
Molly Gallogly
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 30, 2026, 11:43 AM EDT
Completed Phase 1 Interventional

Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction

NCT00313339
View directory record Official record
Conditions
Myocardial Infarction, Coronary Artery Disease
Interventions
Intra-coronary infusion
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 30, 2026, 11:43 AM EDT
Terminated Phase 2 Interventional

Investigation of Neural Stem Cells in Ischemic Stroke

NCT03629275
View directory record Official record
Conditions
Ischemic Stroke, Chronic Stroke, Hemiparesis, Arm Paralysis
Interventions
CTX0E03 Drug Product and delivery device, Placebo
Combination Product · Drug
Lead sponsor
ReNeuron Limited
Industry
Eligibility
35 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
23
States / cities
Little Rock, Arkansas • Irvine, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 30, 2026, 11:43 AM EDT
Completed Phase 2 Interventional

Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma

NCT00028665
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, carmustine, cisplatin, cyclophosphamide, etoposide, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
12 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 30, 2026, 11:43 AM EDT
Completed Phase 2 Interventional

Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

NCT01339572
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Multiple Myeloma
Interventions
Plerixafor, Filgrastim
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 30, 2026, 11:43 AM EDT
Completed No phase listed Observational

Pulmonary Complications of Hematopoietic Stem Cell Transplantation

NCT00837681
View directory record Official record
Conditions
Lung Disease
Interventions
Not listed
Lead sponsor
Karen Wood
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 30, 2026, 11:43 AM EDT
Not listed No phase listed Observational

Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00005900
View directory record Official record
Conditions
I Cell Disease, Fucosidosis, Globoid Cell Leukodystrophy, Adrenoleukodystrophy, Mannosidosis, Niemann-Pick Disease, Pulmonary Complications, Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Metachromatic Leukodystrophy, Gaucher's Disease, Wolman Disease
Interventions
Not listed
Lead sponsor
Fairview University Medical Center
Other
Eligibility
0 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 11:43 AM EDT
Completed Phase 2 Interventional Results available

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

NCT01525407
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Atorvastatin Calcium, Peripheral Blood Stem Cell Transplantation
Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Stanford, California • Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 30, 2026, 11:43 AM EDT
Active, not recruiting Phase 4 Interventional

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT03023631
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Recombinant Human Papillomavirus Nonavalent Vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 30, 2026, 11:43 AM EDT
Completed Phase 2 Interventional

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

NCT00055653
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, cyclosporine, fludarabine phosphate, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
25
States / cities
Duarte, California • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 30, 2026, 11:43 AM EDT
Completed Phase 2 Interventional Results available

Cellular Therapy With Cord Blood Cells

NCT00427557
View directory record Official record
Conditions
Multiple Myeloma, Leukemia, Lymphoma
Interventions
Fludarabine, Melphalan, Umbilical Cord Blood, Rituximab, Peripheral Blood Stem Cell Infusion
Drug · Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 30, 2026, 11:43 AM EDT
Not yet recruiting Phase 2 Interventional

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

NCT07524530
View directory record Official record
Conditions
Core Binding Factor Alpha Subunits, Hematologic Neoplasms, Leukemia, Lymphoma
Interventions
Cyclophosphamide, Busulfan, Fludarabine, Total Body Irradiation, Hematopoietic stem cells, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 11:43 AM EDT
Terminated Phase 2 Interventional Results available

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

NCT01518153
View directory record Official record
Conditions
Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
Interventions
Fludarabine, Melphalan, Alemtuzumab, Stem Cell Infusion, Tacrolimus, Methotrexate, G-CSF, Low Dose Donor T-Cells, High Dose Donor T-Cells
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 30, 2026, 11:43 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy

NCT00225095
View directory record Official record
Conditions
Recovery Following Partial Medial Meniscectomy
Interventions
Mesenchymal Stem Cells, Hyaluronan
Drug
Lead sponsor
Mesoblast International Sàrl
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Los Angeles, California • Vero Beach, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Oct 30, 2026, 11:43 AM EDT
Active, not recruiting Phase 2 Interventional

Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

NCT04476901
View directory record Official record
Conditions
Non-ischemic Dilated Cardiomyopathy
Interventions
allogeneic human mesenchymal stem cells (hMSCs), Placebo
Biological · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 80 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Stanford, California • Miami, Florida • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 30, 2026, 11:43 AM EDT